U.S. Markets closed

BriaCell Therapeutics Corp. (BCTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.8800-0.1300 (-2.59%)
At close: 04:00PM EDT
4.9500 +0.07 (+1.43%)
After hours: 05:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.8700
Bid4.8000 x 3200
Ask5.0100 x 900
Day's Range4.7350 - 5.0800
52 Week Range3.1400 - 12.4700
Avg. Volume845,119
Market Cap77.654M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

    PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has activated Hoag Memorial Hospital Presbyterian (“Hoag”) and re-engaged Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, as two additional clinical sites

  • GlobeNewswire

    BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

    U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer.Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients.BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase I/IIa study, now with Fast Track designation. PHILADELPHIA and VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWS

  • GlobeNewswire

    BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022

    Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy.Bria-OTS™ will be used to treat patients with advanced breast cancer, providing patients with readily available personalized treatment. PHILADELPHIA and VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializin